Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.67 USD
Change Today +0.04 / 1.10%
Volume 393.4K
CPRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 3:21 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

catalyst pharmaceuticals inc (CPRX) Snapshot

Open
$3.44
Previous Close
$3.63
Day High
$3.73
Day Low
$3.36
52 Week High
07/21/15 - $5.80
52 Week Low
10/14/14 - $2.26
Market Cap
306.4M
Average Volume 10 Days
879.9K
EPS TTM
$-0.22
Shares Outstanding
83.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CATALYST PHARMACEUTICALS INC (CPRX)

Related News

No related news articles were found.

catalyst pharmaceuticals inc (CPRX) Related Businessweek News

No Related Businessweek News Found

catalyst pharmaceuticals inc (CPRX) Details

Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders. The company offers Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It is also involved in the development of CPP-115, a GABA aminotransferase inhibitor, which is in Phase Ib clinical trial for the treatment of epilepsy and other selected neurological indications, such as complex partial seizures and Tourette Syndrome; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceuticals, Inc. has a strategic collaboration agreement with BioMarin Pharmaceutical, Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

12 Employees
Last Reported Date: 03/13/15
Founded in 2002

catalyst pharmaceuticals inc (CPRX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $510.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $288.0K
Chief Operating Officer and Chief Scientific ...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

catalyst pharmaceuticals inc (CPRX) Key Developments

Catalyst Pharmaceuticals Appoints Paul J. Merrigan as Chief Commercial Officer

Catalyst Pharmaceuticals, Inc. announced the appointment of Paul J. Merrigan as Chief Commercial Officer. Mr. Merrigan will be responsible for leading Catalyst's marketing, sales and commercial operations. He replaces Richard Daly, who served as interim Chief Commercial Officer during the search. Mr. Daly will continue in his role as a member of the board of directors. Paul brings a wealth of commercial experience to Catalyst from a variety of senior roles at several leading rare disease biopharmaceutical companies. In addition, Paul has extensive knowledge in the commercialization of novel therapeutics for orphan indications and specific knowledge in commercialization of therapeutics for rare neuromuscular disorders. Prior to joining Catalyst, Mr. Merrigan served as Vice President, Global Marketing at Aegerion Pharmaceuticals. Mr. Merrigan was previously Vice President and General Manager of Neuromuscular Diseases at Genzyme Corporation.

Catalyst Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Catalyst Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported Loss from operations was $4,897,330 compared with $2,990,173 for the same period last year. Loss before income taxes was $4,558,503 compared with $3,198,020 for the same period last year. Net loss was $4,558,503 or $0.06 basic and diluted per share compared with $3,198,020 or $0.05 basic and diluted per share for the same period last year. Non-GAAP net loss was $4,892,459 or 6 cents per basic and diluted share for the second quarter of 2015. In comparison, Non-GAAP net loss for the second quarter of 2014 was $2,974,429, or 5 cents per basic and diluted share, which excludes non-cash expense of $223,591 attributable to the change in fair value of liability-classified warrants. For the six months, the company reported Loss from operations was $9,189,245 compared with $6,498,538 for the same period last year. Loss before income taxes was $9,968,762 compared with $7,009,139 for the same period last year. Net loss was $9,968,762 or $0.13 basic and diluted per share compared with $7,009,139 or $0.12 basic and diluted per share for the same period last year. Non-GAAP net loss was $9,122,440 or 12 cents per basic and diluted share for the first six months of 2015. In comparison, Non-GAAP net loss for the first six months of 2014 was $6,450,034, or 11 cents per basic and diluted share, which excludes non-cash expense of $559,105 attributable to the change in fair value of liability-classified warrants.

Catalyst Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Catalyst Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPRX:US $3.67 USD +0.04

CPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPRX.
View Industry Companies
 

Industry Analysis

CPRX

Industry Average

Valuation CPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALYST PHARMACEUTICALS INC, please visit www.catalystpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.